Vanguard Group Inc. raised its holdings in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 0.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,128,884 shares of the biotechnology company’s stock after purchasing an additional 24,998 shares during the period. Vanguard Group Inc. owned approximately 9.24% of Repligen worth $959,665,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Hanseatic Management Services Inc. purchased a new stake in Repligen during the 3rd quarter valued at $27,000. IFP Advisors Inc boosted its stake in shares of Repligen by 34.3% in the 3rd quarter. IFP Advisors Inc now owns 227 shares of the biotechnology company’s stock worth $51,000 after buying an additional 58 shares during the last quarter. Meeder Asset Management Inc. boosted its stake in shares of Repligen by 18.9% in the 2nd quarter. Meeder Asset Management Inc. now owns 340 shares of the biotechnology company’s stock worth $55,000 after buying an additional 54 shares during the last quarter. Ellevest Inc. boosted its stake in shares of Repligen by 507.0% in the 3rd quarter. Ellevest Inc. now owns 346 shares of the biotechnology company’s stock worth $65,000 after buying an additional 289 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in shares of Repligen by 88.4% in the 2nd quarter. Quadrant Capital Group LLC now owns 373 shares of the biotechnology company’s stock worth $61,000 after buying an additional 175 shares during the last quarter. 91.00% of the stock is currently owned by hedge funds and other institutional investors.
Repligen Stock Up 1.7 %
NASDAQ:RGEN opened at $169.09 on Tuesday. The business’s 50-day simple moving average is $181.25 and its two-hundred day simple moving average is $186.60. The stock has a market cap of $9.39 billion, a PE ratio of 52.03, a P/E/G ratio of 2.62 and a beta of 1.09. Repligen Co. has a 52 week low of $137.21 and a 52 week high of $262.26.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on RGEN. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a research note on Thursday, February 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on Repligen in a research note on Tuesday, December 13th. They issued a “hold” rating and a $180.00 price target on the stock. Craig Hallum lowered their target price on Repligen from $251.00 to $220.00 in a research report on Thursday, February 23rd. Royal Bank of Canada assumed coverage on Repligen in a research report on Tuesday, December 6th. They set a “sector perform” rating and a $190.00 target price on the stock. Finally, KeyCorp lowered their target price on Repligen from $260.00 to $240.00 and set an “overweight” rating on the stock in a research report on Thursday, February 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $216.86.
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs.
- Get a free copy of the StockNews.com research report on Repligen (RGEN)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN – Get Rating).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.